Body mass index–associated differences in response to ovulation induction with letrozole

McKnight, Katherine; Nodler, J.L.; Cooper, H. John; Chapman, Victoria; Cliver, Suzanne P.; Bates, G. Wright

doi:10.1016/j.fertnstert.2011.08.002

Cited by 24 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Basal testosterone level is a good marker for pregnancy outcome and quantity of dominant follicles on HCG day in women with reduced ovarian reserve but not in women with normal range of serum FSH [18]. Letrozole is an effective ovulation induction drug in elevated-BMI women [19]. We had not any correlation between BMI, basal testosterone, LH/FSH, and number of mature follicle because according to inclusion criteria all of the patients had normal testosterone level, BMI, and LH/FSH ratio.…”

Section: Discussionmentioning

confidence: 99%

Dosage Optimization for Letrozole Treatment in Clomiphene-Resistant Patients with Polycystic Ovary Syndrome: A Prospective Interventional Study

Rahmani

Ahmadi

Motamed

et al. 2012

Obstetrics and Gynecology International

View full text Add to dashboard Cite

Objective. Dose adjustment for induction of ovulation is one of the most important problem. Methods. In a prospective interventional study, 44 clomiphene-resistant infertile patients (113 cycles) were selected from the Abolfazl Infertility Clinic of Bushehr University of Medical Sciences. Letrozole was given orally in a dose of 2.5 mg, 5 mg, and 7.5 mg, respectively. If the patient displayed no response, the dosage was increased. Results. In this patients ovulation occurred in 50 cycles (44.24%), clinical pregnancy rate according to number of cycles was 23.89% (27 of 113 cycles) and according to the number of patients was 61.36% (27 of 44 patients). In the 2.5, 5, and 7.5 groups, follicles occurred in 22.9%, 42.1%, and 85.18% of cycles, and pregnancy rate was 14.58%, 28.94% and, 33.33%, respectively. Conclusions. It is better to administer Letrozole at a lower dosage to prevent complications and increase the dose based on sonographic results antral follicular count, anti-Müllerian hormone, LH/FSH, and estradiol.

show abstract

Section: Discussionmentioning

confidence: 99%

Dosage Optimization for Letrozole Treatment in Clomiphene-Resistant Patients with Polycystic Ovary Syndrome: A Prospective Interventional Study

Rahmani

Ahmadi

Motamed

et al. 2012

Obstetrics and Gynecology International

View full text Add to dashboard Cite

show abstract

“…Regarding the role of BMI, data are limited. A recent study has shown no difference in the outcome between women with a BMI <30 kg/m 2 and BMI 30 kg/m 2 [55].…”

Section: Aromatase Inhibitorsmentioning

confidence: 92%

Polycystic ovaries and obesity

Messinis

Messini

Anifandis

et al. 2015

Best Practice & Research Clinical Obstetrics & Gynaecol

View full text Add to dashboard Cite

“…Increasing BMI may also negatively affect ovulation rates with CC, especially in women with PCOS. 29 One study of 44 CC-resistant PCOS patients showed no difference in response to letrozole based on BMI. However, that study included women with a small range of BMIs: 29 3.59 kg/m 2 .…”

Section: Discussionmentioning

confidence: 99%

Effects of letrozole alone or letrozole in combination with low-dose intramuscular injection of human menopausal gonadotropin on ovulation and pregnancy of 150 patients with polycystic ovary syndrome

Ahmad

Muzaffar

Bashir

et al. 2020

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Objective of the study was to explore the effects of letrozole (LE) in combination with low-dose intramuscular injection of human menopausal gonadotropin (HMG) on the ovulation induction and pregnancy of patients with polycystic ovary syndrome (PCOS).Methods: The study comprised of 150 couples who were randomly divided into two groups of 75 each. Group “A” received letrozole (LE) in a dose of 2.5 mg to 5mg /d. LE was started orally starting on 3rd to 5th day of menstrual cycle for 5 consecutive days. Group “B” received letrozole in a dose of 2.5 to 5 mg/day starting on the 3rd to 5th day of menstrual cycle for 5 consecutive days. Starting from the day of oral administration of letrozole, 75 IU HMG was injected intramuscularly on alternate days for 5 consecutive doses. The ovulation induction parameters and pregnancy outcomes were observed.Results: The Group A (LE group) had the most completed cycle (310 cycles), 157 (52.3%) of which had ovulation. The Group B (LE+HMG) group completed the fewest cycles (258 cycles), with 168 (65.1%) of them ovulating. This difference was statistically significant (P<0.05). On HCG injection day, both the endometrial thickness (11.5±1.2) and number of mature follicles (2.1±1.3) of the Group B were significantly higher than those of Group A (P<0.001), but the follicle diameters were similar (P>0.05) The pregnancy rate of the Group B was 54.7%, which was significantly higher than that of the Group A (29.3 %) (P<0.05) The average medication cycle of the Group B group was significantly shorter than that of the Group A (P<0.05).Conclusions: The regimen using LE in combination with low-dose intramuscular injection of HMG has satisfactory therapeutic effects on ovulation induction, short medication cycle and high clinical pregnancy rate, which is promising for treating patients with PCOS infertility.

show abstract

Body mass index–associated differences in response to ovulation induction with letrozole

Cited by 24 publications

References 12 publications

Dosage Optimization for Letrozole Treatment in Clomiphene-Resistant Patients with Polycystic Ovary Syndrome: A Prospective Interventional Study

Dosage Optimization for Letrozole Treatment in Clomiphene-Resistant Patients with Polycystic Ovary Syndrome: A Prospective Interventional Study

Polycystic ovaries and obesity

Effects of letrozole alone or letrozole in combination with low-dose intramuscular injection of human menopausal gonadotropin on ovulation and pregnancy of 150 patients with polycystic ovary syndrome

Contact Info

Product

Resources

About